公开(公告)号：US20050287201A1

公开(公告)日：2005-12-29

申请号：US11135271

申请日：2005-05-24

Applicant: Jonathan Till ,  Ronald Blum ,  William Kokonaski ,  Dwight Duston

Inventor： Jonathan Till ,  Ronald Blum ,  William Kokonaski ,  Dwight Duston

IPC: A61F2/14 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51

CPC classification number: A61K9/1075 ,  A61K9/0009 ,  A61K9/0048

Abstract: Embodiments of the present invention relate to a method for delivering pharmaceuticals to the lens of the eye to treat or prevent presbyopia. According to the embodiments, pharmaceuticals may be applied by providing the pharmaceuticals to the eye and promoting delivery of the pharmaceuticals into the lens capsule and/or lens fibers of the lens of the eye. Methods include iontophoresis, nano-medication, and photonic activation to deliver the pharmaceuticals to treat or prevent presbyopia.

Abstract translation: 本发明的实施方案涉及将药物输送到眼睛的晶状体以治疗或预防老花眼的方法。 根据实施方案，可以通过向眼睛提供药物并促进将药物递送到眼睛晶状体的晶状体囊和/或透镜纤维中来应用药物。 方法包括离子电渗疗法，纳米药物治疗和光子激活以递送药物以治疗或预防老花眼。

公开(公告)号：US20050112113A1

公开(公告)日：2005-05-26

申请号：US10969868

申请日：2004-10-22

Applicant: Jonathan Till ,  Ronald Blum

Inventor： Jonathan Till ,  Ronald Blum

IPC: A61F9/013 ,  A61K38/06 ,  A61K38/45 ,  A61K41/00 ,  A61K38/43 ,  A61F2/14

CPC classification number: A61K41/00 ,  A61F9/013 ,  A61K31/74 ,  A61K38/05 ,  A61K38/063 ,  A61K38/44 ,  A61K38/45 ,  A61K41/0019 ,  A61K41/0023 ,  A61K41/0042 ,  A61K47/556 ,  A61K2300/00

Abstract: Embodiments of the present invention relate to methods and pharmacological compositions to treat presbyopia in the human eye. According to the embodiments, pharmacological compositions may be applied to an eye to effect a change in the accommodative ability of the eye by the breaking and reduction of lenticular bonds in the eye that may be responsible for presbyopia. The compositions may be applied in an inactive state and subsequently be activated to achieve a therapeutic effect.

Abstract translation: 本发明的实施方案涉及治疗人眼中的老花眼的方法和药物组合物。 根据实施方案，可以将药物组合物施用于眼睛，以通过破坏和减少可能导致老花眼造成的眼睛中的透镜状结合键来改变眼睛的调节能力。 组合物可以以非活性状态施用，随后被激活以达到治疗效果。

公开(公告)号：US20050101677A1

公开(公告)日：2005-05-12

申请号：US11010436

申请日：2004-12-14

Applicant: Jonathan Till

Inventor： Jonathan Till

IPC: A61F9/013 ,  A61K38/06 ,  A61K38/45 ,  A61K41/00 ,  A61K31/095 ,  A61K31/01 ,  A61N1/30

CPC classification number: A61F9/013 ,  A61F9/0017 ,  A61F9/007 ,  A61F9/0079 ,  A61K9/0048 ,  A61K38/063 ,  A61K38/45 ,  A61K41/00 ,  A61K41/0023 ,  A61K41/0042

Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.